Viral pneumonia is thought to be the most common non-obstetric infectious disease 1 during pregnancy, which is associated with maternal and neonatal morbidity and mortality 2 during pregnancy [1] . Atypical pneumonia known as coronavirus disease (COVID-19) caused by 3 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly infectious and is 4 currently spreading rapidly around the globe [2] . Before leading to the global emergency, SARS- an infection history of a maximum of 7 days. However, more studies are needed in the aspects of 11 maternal and neonatal outcomes of pregnant women. This case series study was conducted to 12 assess the impact of COVID-19 infection on adverse pregnancy outcomes. In this study, the 13 duration from onset of infection to the delivery was 1-26 days. Both healthcare workers and 14 general infected women were included in the study.
15
We conducted a case series study on pregnant women (n =17 in five. Other common symptoms were cough (n = 6), diarrhea (n = 3), nasal congestion (n = 2), 2 shortness of breath (n = 2), and sputum production (n = 1 
21
Out of the seventeen neonates, we observed neonatal pneumonia in five neonates.
22
Similarly, in fifteen neonates, COVID-19 was not detected in the throat swab. The swab samples 23 tested within 24 hours after the delivery, were positive in only two neonates (case 6 and case 14). 4/17 (23.5% and 0.63-2.37) 4 out of 17 patients were found with lymphopenia, which could be linked with COVID-19 infection Elevated ALT (>45 U/L) 2/17 (11.7% and 9-46) Two out of 17 patients were found with elevated AST and/or ALT. however, the majority of the patients had normal ALT and AST levels. Elevated AST (>35 U/L) 2/17 (11.7% and 12-39) 4/17 (23.5% and 0.63-2.37) 4 out of 17 patients were found with lymphopenia, which could be linked with COVID-19 infection Elevated ALT (>45 U/L) 2/17 (11.7% and 9-46) Two out of 17 patients were found with elevated AST and/or ALT. however, the majority of the patients had normal ALT and AST levels. Elevated AST (>35 U/L) 2/17 (11.7% and 12-39) 
